PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 77.8% | -25.9% | -52.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | -$0 | $0 |
| G&A Expenses | $0 | $0 | -$0 | $0 |
| SG&A Expenses | $0 | $0 | -$0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -7,956.3% | -9,395.7% | 54,094.7% | -8,530.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -8,067.8% | -9,648.7% | 55,588.6% | -9,529.6% |
| EPS | -0.34 | -0.23 | 1.82 | -0.66 |
| % Growth | -47.8% | -112.6% | 375.8% | – |
| EPS Diluted | -0.34 | -0.23 | 1.82 | -0.66 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -7,666.3% | -8,882.1% | 54,478.2% | -9,424.5% |